

U. S. PATENT AND TRADEMARK OFFICE
DEPARTMENT OF COMMERCE

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371**

ATTORNEY'S DOCKET NUMBER

BY0006

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

10/544261

INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE
PCT/JP2004/001326 9 February 2004

PRIORITY DATE CLAIMED
10 February 2003

TITLE OF INVENTION
MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISTS CONTAINING PIPERIDINE DERIVATIVES AS THE
ACTIVE INGREDIENT

APPLICANT(S) FOR DO/EO/US

Minoru Moriya, Toshihiro Sakamoto, Makoto Ishikawa, Akio Kanatani, and Takehiro Fukami

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. This is an express request to begin national examination procedures [35 U.S.C. 371(f)]. The submission must include items (5), (6), (9) and (21) indicated below.
4. The US has been elected (PCT Article 31).
5. A copy of the International Application as filed [35 U.S.C. 371(c)(2)]
 - a. is attached hereto (required only if not communicated by the International Bureau).
 - b. has been communicated by the International Bureau.
 - c. is not required, as the application was filed in the United States Receiving Office (RO/US).
6. An English language translation of the International Application as filed [35 U.S.C. 371(c)(2)].
 - a. is attached hereto
 - b. has been previously submitted under 35 U.S.C. 154(d)(4).
7. Amendments to the claims of the International Application under PCT Article 19 [35 U.S.C. 371(c)(3)].
 - a. are attached hereto (required only if not communicated by the International Bureau).
 - b. have been communicated by the International Bureau.
 - c. have not been made; however, the time limit for making such amendments has NOT expired.
 - d. have not been made and will not be made.
8. An English language translation of the amendments to the claims under PCT Article 19 [35 U.S.C. 371(c)(3)].
9. An oath or declaration of the inventor(s) [35 U.S.C. 371(c)(4)].
10. An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 [35 U.S.C. 371(c)(5)].

Items 11 to 20 below concern other document(s) or information included:

11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. A preliminary amendment.
14. An Application Data Sheet under 37 CFR 1.76.
15. A substitute specification.
16. A power of attorney and/or change of address letter.
17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.
18. A second copy of the published International Application under 35 U.S.C. 154(d)(4).
19. A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
20. Other items or information:

JC09 Rec'd PCT/PTO 03 AUG 2005

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)	INTERNATIONAL APPLICATION NO.	ATTORNEY'S DOCKET NUMBER
10/54461 PCT/JP2004/001326		BY0006P
The following fees are submitted:		
21. <input checked="" type="checkbox"/> Basic national fee.....\$300 22. <input checked="" type="checkbox"/> Examination fee (37 CFR 1.492(c)) If the written opinion prepared by ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4).....\$0 All other situations.....\$200		
23. <input checked="" type="checkbox"/> Search fee (37 CFR 1.492(b)) If the written opinion of the ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4).....\$0 Search fee [37 CFR 1.445(a)(2)] has been paid on the international application to the USPTO as an International Searching Authority.....\$100 International Search Report prepared by an ISA other than the US and provided to the Office or previously communicated to the US by the IB\$400 All other situations.....\$500		
TOTAL OF 21, 22 and 23=		
\$900.00		
<input type="checkbox"/> Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.		
Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof (round up to a whole number)
90 - 100 =	0 /50	0 = 0
X \$250.00		
\$0.00		
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date [37 CFR 1.492(e)].		
CLAIMS	NUMBER FILED	NUMBER EXTRA
Total Claims	21 - 20 =	1
Independent Claims	3 - 3 =	0
MULTIPLE DEPENDENT CLAIM(S) (if applicable)		+ \$360.00
TOTAL OF ABOVE CALCULATIONS (SUBTOTAL)		=
		\$950.00
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).		
+ \$950.00		
Fee for recording the enclosed assignment [37 CFR 1.21(h)]. The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property.		
+ \$950.00		
TOTAL FEES ENCLOSED = \$950.00		
a. <input type="checkbox"/> A check in the amount of \$ _____ to cover the above fees is enclosed. b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. <u>13-2755</u> in the amount of <u>\$950.00</u> to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to the Deposit Account No. <u>13-2755</u> . A duplicate copy of this sheet is enclosed.		Amount to be refunded:
		Amount to be charged:
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive [37 CFR 1.137(a) or (b)] must be filed and granted to restore the International Application to pending status.		
SEND ALL CORRESPONDENCE TO:		
Customer No. 000210 MERCK & CO., INC. Patent Department, RY60-30 P.O. Box 2000 126 East Lincoln Avenue Rahway, New Jersey 07065-0970		
 SIGNATURE <u>CATHERINE D. FITCH</u> NAME		
DATE: <u>August 3, 2005</u> PHONE #: <u>(732) 594-4283</u> 36,502 REGISTRATION NUMBER		

10/544261

JC09 Re PCT/PTO 03 AUG 2005

Page 1A of TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING
A FILING A UNDER 35 U.S.C. 371

Serial No. PCT/JP2004/001326
Case Docket No.: BY0006P
International Filing Date: 9 February 2004
Title: MELANIN-CONCENTRATING HORMONE
RECEPTOR ANTAGONISTS CONTAINING
PIPERIDINE DERIVATIVES AS THE ACTIVE
INGREDIENT

Inventors: MINORU MORIYA, TOSHIHIRO SAKAMOTO,
MAKOTO ISHIKAWA, AKIO KANATANI, and
TAKEHIRO FUKAMI

EXPRESS MAIL CERTIFICATE

DATE OF DEPOSIT August 3, 2005

EXPRESS MAIL NO. EL989586629US

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING
DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS
EXPRESS MAIL "POST OFFICE TO ADDRESSEE" BEFORE
5 P.M. ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO
COMMISSIONER OF PATENTS AND TRADEMARKS, BOX PCT,
WASHINGTON D.C. 20231.

MAILED BY Linda Zelree DATE August 3, 2005